These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

62 related articles for article (PubMed ID: 637951)

  • 1. [Clinical analysis of patients recovered from persistent vegetative state, with special emphasis on the therapeutic and prophylactic effects of L-DOPA (author's transl)].
    Higashi K; Hatano M; Abiko S; Fukuda Y; Noda S; Yamashita T; Kaku R
    No To Shinkei; 1978 Jan; 30(1):27-35. PubMed ID: 637951
    [No Abstract]   [Full Text] [Related]  

  • 2. [Cerebrospinal fluid amine metabolites and L-dopa in vegetative state patients (author's transl)].
    Inagawa T; Ishikawa S; Uozumi T
    No Shinkei Geka; 1978 Mar; 6(3):235-43. PubMed ID: 643153
    [No Abstract]   [Full Text] [Related]  

  • 3. [Results of L-dopa treatment in parkinsonism (author's transl)].
    Kolasa M; Reichowa J; Bieniowa A
    Przegl Lek; 1976; 33(3):407-10. PubMed ID: 1273335
    [No Abstract]   [Full Text] [Related]  

  • 4. Arousal response in hepatic encephalopathy with L-Dopa.
    Weiss A; Pitman ER; Javdan P
    Am J Gastroenterol; 1974 Dec; 62(6):497-503. PubMed ID: 4447098
    [No Abstract]   [Full Text] [Related]  

  • 5. The place of L-dopa/carbidopa in persistent vegetative state.
    Ugoya SO; Akinyemi RO
    Clin Neuropharmacol; 2010; 33(6):279-84. PubMed ID: 21060281
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Long-term prognostic factors in Parkinson's disease (author's transl)].
    Guillard A; Chastang C
    Rev Neurol (Paris); 1978 May; 134(5):341-54. PubMed ID: 725403
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Improved therapeutic response to L-dopa in Parkinson's disease, when combined with bromocriptine (author's transl)].
    Ulm G
    Nervenarzt; 1981 Feb; 52(2):116-20. PubMed ID: 7219619
    [No Abstract]   [Full Text] [Related]  

  • 8. [Polygraphic analysis of nocturnal sleep in subjects affected by bilateral facial spasm, prior to and following L-DOPA administration (author's transl)].
    Di Perri R; Di Rosa AE; Meduri M; Messina C
    Riv Patol Nerv Ment; 1974 Oct; 95(5):662-72. PubMed ID: 4470266
    [No Abstract]   [Full Text] [Related]  

  • 9. [The problem of side effects after a treatment with L-dopa in the Parkinson's syndrome: clinical and animal studies (author's transl)].
    Sommer H; Fischer GJ; Quandt J
    Folia Clin Int (Barc); 1974 Oct; 24(10):681-95. PubMed ID: 4279185
    [No Abstract]   [Full Text] [Related]  

  • 10. [Treatment of Parkinson's syndrome with L-dopa and L-carbidopa (author's transl)].
    Hanzal F
    MMW Munch Med Wochenschr; 1976 May; 118(20):653-6. PubMed ID: 818540
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Parosmia and anosmia under L-dopa therapy (author's transl)].
    Neundörfer B; Valdivieso T
    Nervenarzt; 1977 May; 48(5):283-4. PubMed ID: 895952
    [No Abstract]   [Full Text] [Related]  

  • 12. [Pharmacokinetic and pharmacodynamic aspects of L-DOPA treatment and dopadecarboxilase inhibitors and dopaminergic antagonists in Parkinson's disease (author's transl)].
    García de Yébenes J; Avila C; Bazán E; García E; Gervás J; Maseda C; Mena M; Muradas V; Ramos JA
    Med Clin (Barc); 1982 Apr; 78(7):259-64. PubMed ID: 7087591
    [No Abstract]   [Full Text] [Related]  

  • 13. [Clinical significance of pyridoxine administration in L-dopa therapy of Parkinsonism (author's transl)].
    Namba S; Ishimitsu H; Nakasone S
    No To Shinkei; 1980 Oct; 32(10):991-1000. PubMed ID: 6159908
    [No Abstract]   [Full Text] [Related]  

  • 14. [The combined treatment of Parkinson's disease with L-dopa plus decarboxylase inhibitors (carbidopa, benserazide) (author's transl)].
    Podiwinsky F; Mentasti M; Riederer P; Birkmayer W
    Wien Klin Wochenschr; 1979 May; 91(10):332-7. PubMed ID: 452602
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Sustained levodopa efficacy in parkinsonism. Results of a four-year long-term follow-up study (author's transl)].
    Schneider E; Fischer PA; Jacobi P
    Nervenarzt; 1977 Apr; 48(4):205-10. PubMed ID: 404579
    [No Abstract]   [Full Text] [Related]  

  • 16. [Haloperidol, reserpine, l-dopa and amantidine in the treatment of Huntington chorea (author's transl)].
    Candelise L
    Riv Patol Nerv Ment; 1976; 96(1):54-62. PubMed ID: 134449
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disturbed intracortical excitability in early Parkinson's disease is l-DOPA dose related: a prospective 12-month paired TMS study.
    Bares M; Kanovský P; Rektor I
    Parkinsonism Relat Disord; 2007 Dec; 13(8):489-94. PubMed ID: 17449315
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Accuracy of acute levodopa challenge for clinical prediction of sustained long-term levodopa response as a major criterion for idiopathic Parkinson's disease diagnosis.
    Merello M; Nouzeilles MI; Arce GP; Leiguarda R
    Mov Disord; 2002 Jul; 17(4):795-8. PubMed ID: 12210878
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Outcome of Parkinsonism after two years of levodopa plus R04-4602 (author's transl)].
    Faglioni P; Gasparini M; Spinnler H
    Riv Patol Nerv Ment; 1975; 96(4):270-86. PubMed ID: 785578
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Long-term study on the anti-rigidity effect of L-dopa and a decarboxylase inhibitor (ro 8-0576) (author's transl)].
    Eisenlohr JJ; Gehlen W
    MMW Munch Med Wochenschr; 1974 Jul; 116(28):1353-6. PubMed ID: 4212699
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.